Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial

International Clinical Psychopharmacology
Charles L BowdenHsin-Nan Lin

Abstract

The objective of this study was to compare the efficacy and safety of valproate and lithium in bipolar I patients experiencing a manic or a mixed episode. This international, randomized, open-label, parallel-group, equivalence study included 268 patients with bipolar I disorder. The starting dose of valproate was 20 mg/kg/day and that of lithium was 800 mg/day. Treatment duration was 12 weeks. The primary outcome measure was mean change in Young Mania Rating Scale score between baseline and study end. Secondary outcome measures were response and remission rates, change in Montgomery and Asberg Depression Rating Scale and Clinical Global Impression Bipolar Disorder instrument score, and occurrence of adverse events. The mean change from baseline in Young Mania Rating Scale score was 15.8+/-5.3 in the lithium group and 17.3+/-9.4 in the valproate group. The 90% confidence interval of the intergroup difference (-0.69; 3.31) was within prespecified equivalence limits. Response rates were 72.6% in the lithium group and 79.5% in the valproate group. Remission rates were 58.5 and 71.9%, respectively. No intergroup differences were observed in median time to treatment response (21 days) or change in Clinical Global Impression Bipolar D...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
Jan 1, 1992·The American Journal of Psychiatry·T W FreemanA C Swann
Jan 11, 1991·Archives of General Psychiatry·H G PopeJ I Hudson
Mar 23, 1994·JAMA : the Journal of the American Medical Association·C L BowdenJ G Small
Nov 24, 1999·International Clinical Psychopharmacology·M BerkS Brook
Jan 5, 2002·The American Journal of Psychiatry·John M Kane
May 15, 2002·The Journal of Clinical Psychiatry·Trisha SuppesUNKNOWN Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder
Jun 4, 2002·The American Journal of Psychiatry·Mauricio TohenGary A Tollefson
Jan 14, 2003·The Journal of Clinical Psychiatry·John M ZajeckaKenneth W Sommerville
Feb 13, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN WFSBP Task Force on Treatment Guidelines for Bipolar Disorders
Jul 2, 2003·The American Journal of Psychiatry·Mauricio TohenRobert W Baker
Apr 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Mauricio TohenJoseph R Calabrese
Nov 17, 2006·The Journal of Clinical Psychiatry·Charles L BowdenUNKNOWN Depakote ER Mania Study Group

❮ Previous
Next ❯

Citations

Feb 18, 2016·Pharmacology, Biochemistry, and Behavior·Mónica Flores-RamosClaudia Becerra Palars
Dec 15, 2015·Journal of Affective Disorders·Alexandra KleimannSermin Toto
Sep 10, 2010·Pharmaceuticals·Kaizad R MunshiJoseph Gonzalez-Heydrich
Sep 10, 2013·Child and Adolescent Psychiatric Clinics of North America·Gabrielle A Carlson
Jun 12, 2012·Comprehensive Psychiatry·Daniel J SaferAlan M Safer
Nov 11, 2011·CNS Neuroscience & Therapeutics·Rasmus W Licht
Jun 25, 2013·Clinical Biochemistry·Radu M Nanau, Manuela G Neuman
Mar 7, 2012·The Australian and New Zealand Journal of Psychiatry·Gin S MalhiMichael Berk
Jun 20, 2018·Bipolar Disorders·Anastasiya NestsiarovichChristophe G Lambert
Jan 11, 2018·Hormone Molecular Biology and Clinical Investigation·Oluchi AbosiJess G Fiedorowicz
Aug 19, 2014·Expert Review of Neurotherapeutics·Genevieve Curran, Arun Ravindran
Jun 4, 2019·The Cochrane Database of Systematic Reviews·Rebecca F McKnightAndrea Cipriani
Oct 18, 2019·The Cochrane Database of Systematic Reviews·Janina JochimAndrea Cipriani
May 6, 2011·Journal of Medical Economics·Shu Chuen Li, Sanjay Kumar Aggarwal
Nov 4, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic
Dec 14, 2017·International Journal of Molecular Sciences·Eunsoo Won, Yong-Ku Kim
Jan 8, 2021·Current Cardiology Reports·Cédric LemogneJess G Fiedorowicz
Jul 16, 2021·Neuroscience and Biobehavioral Reviews·Susana Gomes-da-CostaIsabella Pacchiarotti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.